HighTower Advisors
ADMA icon

HighTower Advisors’s ADMA Biologics ADMA Stock Holding History

HighTower Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Sell
14,734
-1,488
-9% -$13.6K ﹤0.01% 3630
2026
Q1 		$146K Sell
16,222
-9,493
-37% -$150K ﹤0.01% 3567
2025
Q4 		$469K Buy
25,715
+1,618
+7% +$27.3K ﹤0.01% 2684
2025
Q3 		$353K Sell
24,097
-11,059
-31% -$190K ﹤0.01% 2900
2025
Q2 		$640K Buy
35,156
+4,948
+16% +$101K ﹤0.01% 2320
2025
Q1 		$599K Sell
30,208
-69,173
-70% -$1.2M ﹤0.01% 2316
2024
Q4 		$1.7M Buy
99,381
+11,910
+14% +$224K ﹤0.01% 1616
2024
Q3 		$1.75M Buy
87,471
+25,492
+41% +$396K ﹤0.01% 1601
2024
Q2 		$692K Sell
61,979
-11,010
-15% -$92.4K ﹤0.01% 2089
2024
Q1 		$482K Buy
72,989
+1,569
+2% +$8.58K ﹤0.01% 2306
2023
Q4 		$326K Sell
71,420
-1,097
-2% -$4.06K ﹤0.01% 2641
2023
Q3 		$258K Buy
72,517
+38,160
+111% +$147K ﹤0.01% 2715
2023
Q2 		$126K Sell
34,357
-300
-0.9% -$1.11K ﹤0.01% 3022
2023
Q1 		$114K Buy
34,657
+12,434
+56% +$43K ﹤0.01% 2911
2022
Q4 		$86K Buy
22,223
+600
+3% +$1.85K ﹤0.01% 2955
2022
Q3 		$53K Buy
+21,623
New +$51.9K ﹤0.01% 2872
2021
Q2 		– Sell
-12,360
Closed -$22K – 3138
2021
Q1 		$22K Buy
+12,360
New +$28.3K ﹤0.01% 2892

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HighTower Advisors's ADMA Position: Q2 2026 in Review

HighTower Advisors reduced its ADMA Biologics (ADMA) stake by 9.2% in Q2 2026, selling an estimated $13.6K and leaving 14,734 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #3630.

HighTower Advisors first reported a position in ADMA in Q1 2021 and has held it in 17 quarters since. The position peaked at $1.75M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • HighTower Advisors held 14,734 shares of ADMA Biologics worth $123K as of Q2 2026.
  • HighTower Advisors sold 1,488 ADMA Biologics shares in Q2 2026, an estimated $13.6K.
  • ADMA Biologics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3630 holding.
  • HighTower Advisors first reported a position in ADMA Biologics in Q1 2021 and has held it in 17 quarters since.
  • HighTower Advisors's ADMA Biologics position peaked at $1.75M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.